Corvus Pharma CRVS is set to give its latest quarterly earnings report on Tuesday, 2024-11-12. Here's what investors need to know before the announcement.
Analysts estimate that Corvus Pharma will report an earnings per share (EPS) of $-0.10.
The announcement from Corvus Pharma is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Overview of Past Earnings
In the previous earnings release, the company beat EPS by $0.05, leading to a 9.67% increase in the share price the following trading session.
Here's a look at Corvus Pharma's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.12 | -0.11 | -0.12 | -0.12 |
| EPS Actual | -0.07 | -0.12 | -0.14 | -0.12 |
| Price Change % | 10.0% | -12.0% | -6.0% | 1.0% |
Corvus Pharma Share Price Analysis
Shares of Corvus Pharma were trading at $9.45 as of November 08. Over the last 52-week period, shares are up 538.51%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
To track all earnings releases for Corvus Pharma visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
